chr6-116877337-C-A

Variant summary

Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP4_StrongBS1_Supporting

The NM_173560.4(RFX6):​c.62C>A​(p.Ser21Tyr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000665 in 1,612,872 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).

Frequency

Genomes: 𝑓 0.00054 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00068 ( 1 hom. )

Consequence

RFX6
NM_173560.4 missense

Scores

1
18

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:4

Conservation

PhyloP100: 0.725
Variant links:
Genes affected
RFX6 (HGNC:21478): (regulatory factor X6) The nuclear protein encoded by this gene is a member of the regulatory factor X (RFX) family of transcription factors. Studies in mice suggest that this gene is specifically required for the differentiation of islet cells for the production of insulin, but not for the differentiation of pancreatic polypeptide-producing cells. It regulates the transcription factors involved in beta-cell maturation and function, thus, restricting the expression of the beta-cell differentiation and specification genes. Mutations in this gene are associated with Mitchell-Riley syndrome, which is characterized by neonatal diabetes with pancreatic hypoplasia, duodenal and jejunal atresia, and gall bladder agenesis.[provided by RefSeq, Sep 2010]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -3 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.018052548).
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.000545 (83/152318) while in subpopulation NFE AF= 0.000985 (67/68028). AF 95% confidence interval is 0.000795. There are 0 homozygotes in gnomad4. There are 35 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
RFX6NM_173560.4 linkuse as main transcriptc.62C>A p.Ser21Tyr missense_variant 1/19 ENST00000332958.3
RFX6XM_011535589.2 linkuse as main transcriptc.62C>A p.Ser21Tyr missense_variant 1/18

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
RFX6ENST00000332958.3 linkuse as main transcriptc.62C>A p.Ser21Tyr missense_variant 1/191 NM_173560.4 P1
RFX6ENST00000487683.5 linkuse as main transcriptn.126C>A non_coding_transcript_exon_variant 1/145

Frequencies

GnomAD3 genomes
AF:
0.000545
AC:
83
AN:
152200
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000193
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000131
Gnomad ASJ
AF:
0.000865
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000207
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000985
Gnomad OTH
AF:
0.000957
GnomAD3 exomes
AF:
0.000582
AC:
143
AN:
245622
Hom.:
1
AF XY:
0.000583
AC XY:
78
AN XY:
133748
show subpopulations
Gnomad AFR exome
AF:
0.000261
Gnomad AMR exome
AF:
0.0000875
Gnomad ASJ exome
AF:
0.000706
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.000232
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00107
Gnomad OTH exome
AF:
0.000669
GnomAD4 exome
AF:
0.000677
AC:
989
AN:
1460554
Hom.:
1
Cov.:
32
AF XY:
0.000702
AC XY:
510
AN XY:
726498
show subpopulations
Gnomad4 AFR exome
AF:
0.0000598
Gnomad4 AMR exome
AF:
0.0000896
Gnomad4 ASJ exome
AF:
0.000843
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.000163
Gnomad4 FIN exome
AF:
0.0000376
Gnomad4 NFE exome
AF:
0.000823
Gnomad4 OTH exome
AF:
0.000481
GnomAD4 genome
AF:
0.000545
AC:
83
AN:
152318
Hom.:
0
Cov.:
32
AF XY:
0.000470
AC XY:
35
AN XY:
74474
show subpopulations
Gnomad4 AFR
AF:
0.000192
Gnomad4 AMR
AF:
0.000131
Gnomad4 ASJ
AF:
0.000865
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.000207
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000985
Gnomad4 OTH
AF:
0.000947
Alfa
AF:
0.000998
Hom.:
2
Bravo
AF:
0.000570
ESP6500AA
AF:
0.000681
AC:
3
ESP6500EA
AF:
0.000814
AC:
7
ExAC
AF:
0.000626
AC:
76

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Uncertain:3
Uncertain significance, criteria provided, single submitternot providedBreakthrough Genomics, Breakthrough Genomics-- -
Uncertain significance, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpOct 05, 2022This sequence change replaces serine, which is neutral and polar, with tyrosine, which is neutral and polar, at codon 21 of the RFX6 protein (p.Ser21Tyr). This variant is present in population databases (rs146773792, gnomAD 0.1%), including at least one homozygous and/or hemizygous individual. This variant has not been reported in the literature in individuals affected with RFX6-related conditions. ClinVar contains an entry for this variant (Variation ID: 917470). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Uncertain significance, criteria provided, single submitterclinical testingGeneDxApr 03, 2023In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
Monogenic diabetes Uncertain:1
Uncertain significance, criteria provided, single submitterresearchPersonalized Diabetes Medicine Program, University of Maryland School of MedicineJul 27, 2018ACMG criteria: BP4 (REVEL score 0.081 + BP4 (9 predictors); not using PP3 (2 predictors)) -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.094
BayesDel_addAF
Benign
-0.46
T
BayesDel_noAF
Benign
-0.48
CADD
Benign
17
DANN
Benign
0.96
DEOGEN2
Benign
0.083
T
Eigen
Benign
-0.16
Eigen_PC
Benign
-0.22
FATHMM_MKL
Benign
0.27
N
LIST_S2
Benign
0.53
T
M_CAP
Benign
0.024
T
MetaRNN
Benign
0.018
T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
0.0
N
MutationTaster
Benign
1.0
N
PrimateAI
Benign
0.43
T
PROVEAN
Benign
-0.31
N
REVEL
Benign
0.081
Sift
Uncertain
0.0090
D
Sift4G
Benign
1.0
T
Polyphen
0.91
P
Vest4
0.39
MVP
0.34
MPC
0.99
ClinPred
0.025
T
GERP RS
5.3
Varity_R
0.094
gMVP
0.39

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs146773792; hg19: chr6-117198500; API